Michael Casia

Michael Casia serves as the President and Managing Director of Organon Canada, a global healthcare company dedicated to advancing gender equity through its focus on women’s health and strengthening the Canadian healthcare system with cost-saving solutions provided by its biosimilar portfolio.

Under Michael’s leadership, Organon Canada has rapidly evolved into a key player in the Canadian healthcare environment, with active involvement in critical areas such as contraception, fertility, menopause, osteoporosis, and women’s cancers. Additionally, the company has emerged as a market leader in biosimilars, with Michael serving as a vocal advocate for their adoption through his role as Vice-Chair of Biosimilars Canada Industry Association.

Prior to assuming his current leadership role at Organon Canada in 2021, Michael played a pivotal role in Organon’s creation during its spin-off from Merck. As the Chief of Staff for Organon’s Global CEO, Michael contributed to the development of the business case, strategy and the creation of the global organization.

Michael is also a vocal advocate for diversity, equity and inclusion within business and he has embedded these values within Organon Canada. In its first full year of operation, Organon Canada was recognized by “Women in Governance” as a Gender Parity Certified organization, while in 2023 the organization was recognized by Women Leaders in Pharma as “Women’s Empowerment Company of the Year”.

Born and raised in Montreal, Michael has over two decades of experience across a variety of roles within the life science sector, including roles spanning the United States, Belgium, Finland, Switzerland, and France. Most notably, as Managing Director of Merck/MSD Finland, he successfully led the organization to become the #1 multi-national in the country in terms of revenues.

Michael speaks regularly across a range of topics, including women’s health, gender equity, biosimilars and the business case for Diversity, Equity, and Inclusion. He holds an MBA from Columbia Business School in New York and a Bachelor of Science in Biochemistry from McGill University.